{"title":"Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.","authors":"Rafal Hanc, Robin Demuynck, Dmitri V Krysko","doi":"10.1038/s41577-026-01356-5","DOIUrl":"https://doi.org/10.1038/s41577-026-01356-5","url":null,"abstract":"<p><p>Recent studies suggest that the formation of tertiary lymphoid structures (TLSs) could be associated with better survival from certain cancers. In this Perspective, we propose that immunogenic cell death (ICD) can act as an upstream organizer of tumour-associated TLSs by coordinating vascular, stromal and immune reprogramming in the tumour microenvironment. ICD leads to the release of tumour antigens and damage-associated molecular patterns that activate innate pathways, such as cGAS-STING signalling, in dendritic cells, myeloid cells, endothelial cells and stromal fibroblasts. These activated cells release type I interferons, TNF and chemokines, such as CCL19, CCL21 and CXCL13, that promote endothelial cell activation and the differentiation of high endothelial venule-like structures. This enables the recruitment of naive and memory lymphocytes and the emergence of perivascular T cell-dendritic cell aggregates, which can form the basis of TLSs. Full structural maturation of TLSs, with segregated B cell and T cell zones, follicular dendritic cell networks and germinal centres, appears to require additional lymphotoxin β receptor (LTβR)-dependent stromal reprogramming. Together, this suggests a two-step model in which ICD first seeds inflammatory vascular niches and then, through LTβR-mediated tissue organization, supports the development of functional TLSs.</p>","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":" ","pages":""},"PeriodicalIF":47.1,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.","authors":"Sebastian Serve, Max Löhning","doi":"10.1038/s41577-026-01345-8","DOIUrl":"10.1038/s41577-026-01345-8","url":null,"abstract":"<p><p>Interleukin-33 (IL-33) is an alarmin and cytokine that has potent biological effects in various tissues. It acts on a broad array of immune cell populations and is involved in many processes associated with health and disease. This Review discusses the biology of IL-33 and its receptor, ST2, and the functional relevance of IL-33-ST2 signalling. It focuses particularly on the differential regulation of IL-33 sensitivity in distinct cell types in diverse tissue settings. Furthermore, we describe the effects of IL-33 in various diseases, including viral infections, cancer, graft-versus-host disease, colitis, autoimmunity, chronic obstructive pulmonary disease, asthma and allergy. We also consider the roles of IL-33 in physiological reactions such as fat tissue biology and tissue regeneration. The Review aims to provide a comprehensive understanding of IL-33 signalling, including its potential as a target for developing new treatments, and to suggest future research directions.</p>","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":" ","pages":""},"PeriodicalIF":47.1,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148881155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Epigenetic regulation of B cell tolerance and dysfunction in autoimmune disease.","authors":"Shaocun Zhang, Yu Wang, Wanli Liu","doi":"10.1038/s41577-026-01344-9","DOIUrl":"https://doi.org/10.1038/s41577-026-01344-9","url":null,"abstract":"<p><p>Epigenetic regulation orchestrates B cell development, lineage commitment, subset differentiation and activation, and is equally central to the maintenance of B cell self-tolerance. Disruption of epigenetic homeostasis at successive tolerance checkpoints - from central tolerance in the bone marrow to peripheral tolerance at germinal centre and extrafollicular stages - can lead to the emergence of autoreactive B cells and the production of autoantibodies in systemic autoimmune diseases. In this Review, we describe the molecular mechanisms by which multiple epigenetic layers - encompassing DNA methylation, histone modification, chromatin remodelling, non-coding RNA regulation and RNA modification - collectively regulate normal B cell function and, when dysregulated, contribute to autoimmune pathogenesis. We examine how specific epigenetic axes, including microRNA-PI3K signalling, DNA demethylation-histone deacetylation balance and chromosome-linked innate immune receptor control, underpin tolerance checkpoint failure and B cell dysfunction in autoimmune disease. Finally, we discuss emerging epigenetic-targeted therapeutic strategies and highlight future research directions aimed at modulating disease-relevant B cell programmes in systemic autoimmunity.</p>","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":" ","pages":""},"PeriodicalIF":47.1,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Josef Shin, Christina Francisca Vogelaar, Stefan Bittner, Frauke Zipp
{"title":"Immune-mediated excitotoxicity in brain disorders.","authors":"Josef Shin, Christina Francisca Vogelaar, Stefan Bittner, Frauke Zipp","doi":"10.1038/s41577-026-01348-5","DOIUrl":"https://doi.org/10.1038/s41577-026-01348-5","url":null,"abstract":"<p><p>Balanced activity of neuronal and immune networks is essential for maintaining central nervous system (CNS) function and mental health, whereas disturbances in network dynamics often lead to excitotoxicity and progressive pathology across brain diseases. Emerging evidence indicates that immune-mediated mechanisms can shape excitotoxic injury at least as profoundly as classical glutamatergic transmission. Here, we extend the concept of excitotoxicity beyond glutamate receptor overactivation to include innate and adaptive immune pathways, introducing the framework of immune-mediated excitotoxicity. We focus on three illustrative settings: epilepsy and ischaemic injury, where reiterative feedback between neuronal excitation and neuroimmune activation promotes acute excitotoxic damage; neurodegenerative disorders, in which misfolded protein aggregates act as immune stressors that amplify local inflammation; and multiple sclerosis, characterized by persistent, compartmentalized inflammation that drives chronic excitotoxic cycles. Across these examples, we define three hallmarks - feedback, stressor and chronicity - as organizing principles of this paradigm and describe the dynamic communication between neuronal and immune networks that underlies immune-mediated excitotoxicity. Recognizing these neuroimmune interactions as central to CNS homeostasis and - when perturbed - to disease opens up new avenues for therapeutic intervention targeting immune-mediated excitotoxicity.</p>","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":" ","pages":""},"PeriodicalIF":47.1,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Beyond the quick win: rebuilding the foundations of cancer immunotherapy","authors":"Ira Mellman","doi":"10.1038/s41577-026-01352-9","DOIUrl":"10.1038/s41577-026-01352-9","url":null,"abstract":"Checkpoint inhibitors, CAR T cells and bispecific T cell engagers have demonstrated the transformative potential of cancer immunotherapy. However, progress has slowed as efforts have focused on replicating PD-(L)1 blockade successes, highlighting the need for deeper understanding of human cancer immunity.","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":"26 10","pages":"726-727"},"PeriodicalIF":47.1,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Can immunology still surprise itself?","authors":"Laura K. Mackay","doi":"10.1038/s41577-026-01351-w","DOIUrl":"10.1038/s41577-026-01351-w","url":null,"abstract":"The discoveries that have transformed immunology often seem obvious in retrospect. Yet none began as an inevitable destination. They began with observations that did not fit, assumptions that somebody challenged, or questions that nobody yet realized were important. Discovery was the outcome. Surprise was the process.","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":"26 10","pages":"716-717"},"PeriodicalIF":47.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Living in the age of inflammation: the reverse hygiene hypothesis","authors":"Luke A. J. O’Neill","doi":"10.1038/s41577-026-01349-4","DOIUrl":"10.1038/s41577-026-01349-4","url":null,"abstract":"Inflammation seems to permeate many aspects of our lives, with the incidence of inflammatory diseases on the rise and ageing being blamed on it. Will the next 25 years see better ways to treat or prevent inflammation and allow us to live longer and healthier lives?","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":"26 10","pages":"722-723"},"PeriodicalIF":47.1,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Building clinical translation on squares of discovery","authors":"Adrian Hayday","doi":"10.1038/s41577-026-01347-6","DOIUrl":"10.1038/s41577-026-01347-6","url":null,"abstract":"Why do so many promising immunotherapies fail to reach their potential? Adrian Hayday argues that transformative clinical advances depend on protecting specialized ‘squares of discovery’ in which deep understanding and unexpected insights emerge, while building stronger pathways to biotechnology, pharmaceutical development and patient care.","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":"26 10","pages":"718-719"},"PeriodicalIF":47.1,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Why adaptive immunity?","authors":"Caetano Reis e Sousa","doi":"10.1038/s41577-026-01350-x","DOIUrl":"10.1038/s41577-026-01350-x","url":null,"abstract":"Adaptive immunity is indispensable to vertebrates, yet most living organisms defend themselves perfectly well without it. Here, I ask why somatically diversified antigen recognition evolved and whether its original advantage extended beyond host defence.","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":"26 10","pages":"714-715"},"PeriodicalIF":47.1,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}